CLINICAL_TRIALS trial_result · 2017-12-12

Clinical Trial Update: BKM120 for Patients With PI3K-activated Tumors [Phase 2]

Phase 2 trial update for BKM120 in PI3K-activated tumors; study completed with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Novartis Pharmaceuticals | Conditions: PI3K Pathway Activated Tumors | Phase 2 | Status: COMPLETED | Results posted: 2017-12-12